Exogenous hormone use and cutaneous melanoma risk in women: The European Prospective Investigation into Cancer and Nutrition.


Journal

International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124

Informations de publication

Date de publication:
15 06 2020
Historique:
received: 21 05 2019
revised: 12 07 2019
accepted: 25 07 2019
pubmed: 12 9 2019
medline: 9 3 2021
entrez: 12 9 2019
Statut: ppublish

Résumé

Evidence suggests an influence of sex hormones on cutaneous melanoma risk, but epidemiologic findings are conflicting. We examined the associations between use of oral contraceptives (OCs) and menopausal hormone therapy (MHT) and melanoma risk in women participating in the European Prospective Investigation into Cancer and Nutrition (EPIC). EPIC is a prospective cohort study initiated in 1992 in 10 European countries. Information on exogenous hormone use at baseline was derived from country-specific self-administered questionnaires. We used Cox proportional hazards regression models to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). Over 1992-2015, 1,696 melanoma cases were identified among 334,483 women, whereof 770 cases among 134,758 postmenopausal women. There was a positive, borderline-significant association between OC use and melanoma risk (HR = 1.12, 95% CI = 1.00-1.26), with no detected heterogeneity across countries (p

Identifiants

pubmed: 31506954
doi: 10.1002/ijc.32674
doi:

Substances chimiques

Contraceptives, Oral, Hormonal 0

Types de publication

Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3267-3280

Subventions

Organisme : Cancer Research UK
ID : 14136
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0401527
Pays : United Kingdom
Organisme : Medical Research Council
ID : G1000143
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N003284/1
Pays : United Kingdom

Informations de copyright

© 2019 UICC.

Références

Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86.
Schadendorf D, van Akkooi ACJ, Berking C, et al. Melanoma. Lancet Lond Engl 2018;392:971-84.
Belbasis L, Stefanaki I, Stratigos AJ, et al. Non-genetic risk factors for cutaneous melanoma and keratinocyte skin cancers: an umbrella review of meta-analyses. J Dermatol Sci 2016;84:330-9.
Kyrgidis A, Lallas A, Moscarella E, et al. Does pregnancy influence melanoma prognosis? A meta-analysis. Melanoma Res 2017;27:289-99.
Johansson ALV, Andersson TM-L, Plym A, et al. Mortality in women with pregnancy-associated malignant melanoma. J Am Acad Dermatol 2014;71:1093-101.
Byrom L, Olsen C, Knight L, et al. Increased mortality for pregnancy-associated melanoma: systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2015;29:1457-66.
Wielowieyska-Szybińska DK, Spałkowska M, Wojas-Pelc A. Melanoma in pregnancy: a case report and review of the literature. Adv Dermatol Allergol 2015;32:483-7.
Mitkov M, Joseph R, Copland J. Steroid hormone influence on melanomagenesis. Mol Cell Endocrinol 2015;417:94-102.
ENHIS 2009 http://www.euro.who.int/__data/assets/pdf_file/0009/97029/4.2.-Incidence-of-melanoma-EDITED_layouted.pdf
Lasithiotakis K, Leiter U, Meier F, et al. Age and gender are significant independent predictors of survival in primary cutaneous melanoma. Cancer 2008;112:1795-804.
Joosse A, de Vries E, Eckel R, et al. Gender differences in melanoma survival: female patients have a decreased risk of metastasis. J Invest Dermatol 2011;131:719-26.
de Vries E, Nijsten TEC, Visser O, et al. Superior survival of females among 10,538 Dutch melanoma patients is independent of Breslow thickness, histologic type and tumor site. Ann Oncol 2008;19:583-9.
Kvaskoff M, Bijon A, Mesrine S, et al. Cutaneous melanoma and endogenous hormonal factors: a large French prospective study. Am J Epidemiol 2011;173:1192-202.
Gandini S, Iodice S, Koomen E, et al. Hormonal and reproductive factors in relation to melanoma in women: current review and meta-analysis. Eur J Cancer 2011;47:2607-17.
IARC. Monographs - combined estrogen-progestogen contraceptives and combined estrogen-progestogen menopausal therapy. CIRC; 2007. Report No.: vol 91. http://monographs.iarc.fr/ENG/Monographs/vol91/index.php
Ameye L, Antoine C, Paesmans M, et al. Menopausal hormone therapy use in 17 European countries during the last decade. Maturitas 2014;79:287-91.
Ghazal S, Pal L. Perspective on hormone therapy 10 years after the WHI. Maturitas 2013;76:208-12.
Bakken K, Fournier A, Lund E, et al. Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2011;128:144-56.
James RE, Lukanova A, Dossus L, et al. Postmenopausal serum sex steroids and risk of hormone receptor-positive and -negative breast cancer: a nested case-control study. Cancer Prev Res 2011;4:1626-35.
Ritte R, Lukanova A, Berrino F, et al. Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study. Breast Cancer Res 2012;14:R76.
Roura E, Travier N, Waterboer T, et al. The influence of hormonal factors on the risk of developing cervical cancer and pre-cancer: results from the EPIC cohort. PLoS One 2016;11:e0147029.
Allen NE, Tsilidis KK, Key TJ, et al. Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investigation into Cancer and Nutrition. Am J Epidemiol 2010;172:1394-403.
Allen NE, Key TJ, Dossus L, et al. Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 2008;15:485-97.
Michaud DS, Gallo V, Schlehofer B, et al. Reproductive factors and exogenous hormone use in relation to risk of glioma and meningioma in a large European cohort study. Cancer Epidemiol Biomarkers 2010;19:2562-9.
Hormonal contraception and post-menopausal hormonal therapy. CIRC; 1999. (IARC monographs of the evaluation of carcinogenic risks to humans). Report No.: 72. https://monographs.iarc.fr/iarc-monographs-on-the-evaluation-of-carcinogenic-risks-to-humans-49/
Cervenka I, Al Rahmoun M, Mahamat-Saleh Y, et al. Postmenopausal hormone use and cutaneous melanoma risk: a French prospective cohort study. Int J Cancer 2019;145:1754-67.
Cervenka I, Mahamat-Saleh Y, Savoye I, et al. Oral contraceptive use and cutaneous melanoma risk : a French prospective cohort study. Int J Cancer 2018;143:2390-9.
Botteri E, Støer NC, Sakshaug S, et al. Menopausal hormone therapy and risk of melanoma: do estrogens and progestins have a different role? Int J Cancer 2017;141:1763-70.
Bhupathiraju SN, Grodstein F, Stampfer MJ, et al. Exogenous hormone use: oral contraceptives, postmenopausal hormone therapy, and health outcomes in the nurses' health study. Am J Public Health 2016;106:1631-7.
Koomen ER, Joosse A, Herings RMC, et al. Estrogens, oral contraceptives and hormonal replacement therapy increase the incidence of cutaneous melanoma: a population-based case-control study. Ann Oncol 2009;20:358-64.
Holly EA, Cress RD, Ahn DK. Cutaneous melanoma in women: ovulatory life, menopause, and use of exogenous estrogens. Cancer Epidemiol Biomark Prev 1994;3:661-8.
Whiteman DC, Watt P, Purdie DM, et al. Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J Natl Cancer Inst 2003;95:806-12.
Carli P, Palli D. Re: Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J Natl Cancer Inst 2003;95:1801 author reply 1801-1802.
Riboli E, Hunt KJ, Slimani N, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr 2002;5:1113-24.
Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med 2007;26:2389-430.
Pintilie M. Analysing and interpreting competing risk data. Stat Med 2007;26:1360-7.
Gefeller O, Hassan K, Wille L. Cutaneous malignant melanoma in women and the role of oral contraceptives. Br J Dermatol 1998;138:122-4.
Karagas MR, Stukel TA, Dykes J, et al. A pooled analysis of 10 case-control studies of melanoma and oral contraceptive use. Br J Cancer 2002;86:1085-92.
Feskanich D, Hunter DJ, Willett WC, et al. Oral contraceptive use and risk of melanoma in premenopausal women. Br J Cancer 1999;81:918-23.
Donley GM, Liu WT, Pfeiffer RM, et al. Reproductive factors, exogenous hormone use and incidence of melanoma among women in the United States. Br J Cancer 2019;120:754-60.
Desai A, Ugorji R, Khachemoune A. Acral melanoma foot lesions. Part 1: epidemiology, aetiology, and molecular pathology. Clin Exp Dermatol 2017;42:845-8.
Tang JY, Spaunhurst KM, Chlebowski RT, et al. Menopausal hormone therapy and risks of melanoma and nonmelanoma skin cancers: women's health initiative randomized trials. J Natl Cancer Inst 2011;103:1469-75.
Simin J, Tamimi R, Lagergren J, et al. Menopausal hormone therapy and cancer risk: an overestimated risk? Eur J Cancer 2017;84:60-8.
Westerdahl J, Olsson H, Måsbäck A, et al. Risk of malignant melanoma in relation to drug intake, alcohol, smoking and hormonal factors. Br J Cancer 1996;73:1126-31.
Lea CS, Holly EA, Hartge P, et al. Reproductive risk factors for cutaneous melanoma in women: a case-control study. Am J Epidemiol 2007;165:505-13.
Richarz NA, Aguilera J, Castillo G, et al. Phototoxic reaction to a combined oral contraceptive (levonorgestrel/ethinylestradiol). Photochem Photobiol Sci 2017;16:1381-3.
Li W-Q, Qureshi AA, Ma J, et al. Personal history of prostate cancer and increased risk of incident melanoma in the United States. J Clin Oncol 2013;31:4394-9.
Zhang M, Qureshi AA, Fortner RT, et al. Teenage acne and cancer risk in US women: a prospective cohort study. Cancer 2015;121:1681-7.
Liu-Smith F, Ziogas A. An age-dependent interaction between sex and geographical UV index in melanoma risk. J Am Acad Dermatol 2017. https://doi.org/10.1016/j.jaad.2017.11.049. [Epub ahead of print].

Auteurs

Iris Cervenka (I)

CESP, Fac. de médecine - Univ. Paris-Sud, Fac. de médecine - UVSQ, INSERM, Université Paris-Saclay, Villejuif, France.
Gustave Roussy, Villejuif, France.

Marie Al Rahmoun (M)

CESP, Fac. de médecine - Univ. Paris-Sud, Fac. de médecine - UVSQ, INSERM, Université Paris-Saclay, Villejuif, France.
Gustave Roussy, Villejuif, France.

Yahya Mahamat-Saleh (Y)

CESP, Fac. de médecine - Univ. Paris-Sud, Fac. de médecine - UVSQ, INSERM, Université Paris-Saclay, Villejuif, France.
Gustave Roussy, Villejuif, France.

Agnès Fournier (A)

CESP, Fac. de médecine - Univ. Paris-Sud, Fac. de médecine - UVSQ, INSERM, Université Paris-Saclay, Villejuif, France.
Gustave Roussy, Villejuif, France.

Marie-Christine Boutron-Ruault (MC)

CESP, Fac. de médecine - Univ. Paris-Sud, Fac. de médecine - UVSQ, INSERM, Université Paris-Saclay, Villejuif, France.
Gustave Roussy, Villejuif, France.

Gianluca Severi (G)

CESP, Fac. de médecine - Univ. Paris-Sud, Fac. de médecine - UVSQ, INSERM, Université Paris-Saclay, Villejuif, France.
Gustave Roussy, Villejuif, France.

Saverio Caini (S)

Cancer Risk Factors and Lifestyle Epidemiology Unit, Cancer Research, Prevention and Oncology Network Institute (ISPRO), Florence, Italy.

Domenico Palli (D)

Cancer Risk Factors and Lifestyle Epidemiology Unit, Cancer Research, Prevention and Oncology Network Institute (ISPRO), Florence, Italy.

Reza Ghiasvand (R)

Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.

Marit B Veierod (MB)

Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.

Edoardo Botteri (E)

Department of Bowel Cancer Screening, Cancer Registry of Norway, Oslo University Hospital, Oslo, Norway.
Norwegian National Advisory Unit for Women's Health, Women's Clinic, Oslo University Hospital, Oslo, Norway.

Anne Tjønneland (A)

Danish Cancer Society Research Center, Copenhagen, Denmark.
University of Copenhagen, Copenhagen, Denmark.

Anja Olsen (A)

Danish Cancer Society Research Center, Copenhagen, Denmark.

Renée T Fortner (RT)

Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Rudolf Kaaks (R)

Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Matthias B Schulze (MB)

Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.
Institute of Nutritional Sciences, University of Potsdam, Nuthetal, Germany.

Salvatore Panico (S)

Dipartimento di medicina clinica e chirurgia, Federico II University, Naples, Italy.

Antonia Trichopoulou (A)

Hellenic Health Foundation, Athens, Greece.

Clio Dessinioti (C)

Hellenic Health Foundation, Athens, Greece.
1st Department of Dermatology Andreas Syggros Hospital University of Athens, Athens, Greece.

Katerina Niforou (K)

Hellenic Health Foundation, Athens, Greece.

Sabina Sieri (S)

Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Via Venezian, Milan, Italy.

Rosario Tumino (R)

Cancer Registry and Histopathology Department, Azienda Sanitaria Provinciale (ASP), Ragusa, Italy.

Carlotta Sacerdote (C)

Unit of Cancer Epidemiology, Città della Salute e della Scienza University-Hospital and Center for Cancer Prevention (CPO), Turin, Italy.

Bas Bueno-de-Mesquita (B)

Department for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
Department of Gastroenterology and Hepatology, University Medical Centre, Utrecht, The Netherlands.
Department of Epidemiology and Biostatistics, The School of Public Health, Imperial College London, St Mary's Campus, London, United Kingdom.
Department of Social & Preventive Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.

Torkjel M Sandanger (TM)

Department of Community Medicine, UiT - The Arctic University of Norway, Tromsø, Norway.

Sandra Colorado-Yohar (S)

Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain.
CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Research Group on Demography and Health, National Faculty of Public Health, University of Antioquia, Medellin, Colombia.

Maria J Sánchez (MJ)

CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Andalusian School of Public Health, Biomedical Research Institute ibs.GRANADA, University of Granada, Granada, Spain.

Leire Gil Majuelo (L)

Public Health Division of Gipuzkoa, Biodonostia Health Research Institute, Ministry of Health of the Basque Government, San Sebastian, Spain.

Leila Lujan-Barroso (L)

Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO-IDIBELL), Gran Via de L'Hospitalet, Barcelona, Spain.

Eva Ardanaz (E)

CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Navarra Public Health Institute, Pamplona, Spain.
IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.

Susana Merino (S)

Public Health Directorate, Asturias, Spain.

Karolin Isaksson (K)

Department of Clinical Sciences Lund, Surgery, Lund University, Skåne University Hospital, Lund, Sweden.

Salma Butt (S)

Department of Clinical Sciences Lund, Surgery, Lund University, Skåne University Hospital, Lund, Sweden.

Ingrid Ljuslinder (I)

Department of Radiation Sciences, Oncology, Norrlands University Hospital, Umeå, Sweden.

Malin Jansson (M)

Department of Surgery and Perioperative Sciences/Surgery, Umeå University, Umeå, Sweden.

Ruth C Travis (RC)

Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.

Kay-Tee Khaw (KT)

University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom.

Elisabete Weiderpass (E)

International Agency for Research on Cancer, Lyon, France.

Laure Dossus (L)

Nutrition and Metabolism Section, International Agency for Research on Cancer, Lyon, France.

Sabina Rinaldi (S)

Nutrition and Metabolism Section, International Agency for Research on Cancer, Lyon, France.

Marina Kvaskoff (M)

CESP, Fac. de médecine - Univ. Paris-Sud, Fac. de médecine - UVSQ, INSERM, Université Paris-Saclay, Villejuif, France.
Gustave Roussy, Villejuif, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH